Cloud-native software company Sophia Genetics has collaborated with Agilent Technologies to deliver a comprehensive solution for cancer analysis.
The partnership will see the SOPHiA DDM Platform integrated with Agilent’s SureSelect Cancer Comprehensive Genomic Profiling (CGP) Assay Kit, which is intended for research use only.
This will allow clinical researchers to precisely detect multiple biomarkers, thereby helping to reduce the risk of missing significant information in cancer samples.
SOPHiA DDM is a cloud-based software-as-a-service platform that helps analyse data from multiple modalities and supports the adoption of data-driven medicine.
Sophia Genetics business development and marketing vice-president Kevin Puylaert said: “Working with Agilent means combining best-in-class profiling practices with rich data and insights.
“Together, we can break traditional barriers that often limit new discoveries, democratising access to data-driven medicine around the world.”
Leveraging the SOPHiA DDM Platform, users will have access to an integrated solution that is aligned with information from the latest guidelines and features reporting tools that are more advanced than readouts.
This partnership will enable labs of varying sizes to bring cancer analysis in-house, removing the need to send samples or output data to other vendors and labs.
Italy-based research and genetics laboratory TomaLab is also involved in an early-access programme that is presently underway.
Agilent integrated genomics division general manager and vice-president Kevin Meldrum said: “We chose to partner with Sophia Genetics to leverage their analytical and reporting capabilities, which complements our SureSelect Cancer CGP panel, to drive toward providing clinical researchers with a complete set of tools that will make comprehensive tumour profiling possible in their own labs.”
In January, Agilent joined forces with Akoya Biosciences for the development of immunohistochemistry diagnostic products for tissue analysis.